Posted on December - 09 - 2011

Study finds ‘massive’ drop in hospital deaths

 

Fewer Canadians are dying after being admitted to hospital, according to a new study comparing death rates across the nation’s hospitals.

Data compiled by the Canadian Institute for Health Information shows that just over half — 53 per cent — of Canadian hospitals have experienced a significant drop in their mortality ratios since the organization began tracking results seven years ago.

The “hospital standardized mortality ratio,” or HSMR, is a ratio of the actual number of in-hospital deaths in a region or hospital compared to the number that would have been expected, based on the national average and the types of patients a hospital sees.

A ratio equal to 100 means there is no difference between a local mortality rate and the average national experience, given the types of patients cared for.

A number greater or less than 100 suggests a hospital’s death rate is higher or lower than the national experience.

Overall, mortality ratios decreased significantly for more than 10 per cent of acute care hospitals in 2010-2011 over the previous year, the study shows.

“We’re continuing to see a decrease in the overall HSMR scores,” said Kira Leeb, director of health system performance at CIHI.

“This continues to be a good news story. Ther

Read more…

Posted on November - 27 - 2011

Lung Cancer’s Hidden Victims: Those Who Never Smoked (HealthDay)

FRIDAY, Dec 2 HealthDay News — Opera legend Beverly Sills never smoked Neither did actress and health advocate Dana Reeve, wife of the late actor Christopher Reeve

And yet in 2007 and 2006, respectively, both joined the ranks of about 32,000 Americans each year who never touch a cigarette but die of lung cancer anyway

In fact, experts say, one in every five cases of the leading cancer killer occurs in nonsmokers The annual death toll among this group now approaches that of breast cancer about 40,000 per year and is roughly equal to that of prostate cancer 32,000 Many never-smoking women may also be unaware that they are more than twice as likely to die of lung cancer as they are of ovarian cancer 14,000 deaths per year

Numbers like those have experts calling for a shift in the publics thinking on lung cancer, away from its label of “the smokers disease”

“We say, If you have a lung, you can get lung cancer,” said Linda Wenger, executive director of Uniting Against Lung Cancer UALC, a nonprofit advocacy group aimed at reaching a better understanding of lung cancer The group was founded after the death in 2001 of Joan Scarangello, an ABC and NBC journalist and lifelong nonsmoker who fell victim at age 47 to lung cancer

“She was very healthy, she was a runner,” Wenger said, but the disease claimed Scarangello as it has many never-smokers “We need to look at lung cancer as being a cancer like any other,” Wenger added

Many experts believe that the stigma around smoking that accompanies lung cancer — that its victims somehow “brought it on themselves” — has dampened public sympathy for patients and hindered funding for research

“The lung cancer research field is definitely the stepchild in the [cancer research] family, and were sure a lot of that has to do with stigma,” said Holli Kawadler, UALCs scientific program director She noted that, in terms of funding received from the US National Cancer Institute, “the numbers are $27,000 in research per cancer death for breast cancer, compared to only about $1,400 per cancer death for lung cancer”

“Its very disheartening for the whole field,” Wenger said “We have a partner out there, his wife has lung cancer but she never smoked And she has the attitude that I never smoked, but cigarettes are going to kill me because the money is not there for research, because of the smoking stigma”

Lung cancers lethal nature may also be hindering efforts to boost awareness and funding for research, experts add

“Unlike other cancers where there is better funding, lung cancer patients arent well enough to really advocate for themselves,” explained Dr James Dougherty, medical and scientific advisor for the Lung Cancer Research Foundation LCRF, based in New York City “When they get the diagnosis they often get sick pretty quickly, so they arent about to publicly take on the role of saying Look, I have a problem, I need help”

Still, even with limited funding, scientists are slowly uncovering clues to the origins and distinct nature of lung cancer in never-smokers One obvious starting point is the fact that women are affected far more often than men

“Among never-smokers with lung cancer, women outnumber men two-to-one,” Wenger said

According to experts at the LCRF, the reasons for the disparity arent clear, but early research is suggesting that, much like breast tumors, lung tumor aggressiveness in women appears linked to estrogen Other factors, as yet unknown, may also be at play

“Were also learning much more about the differences in the biology of [lung cancer in] smokers and nonsmokers,” Dougherty added He pointed to LCRF-funded research under way at MD Anderson Cancer Center in Houston, “specifically looking at some new potential markers on the [tumor] cells of people who have never smoked Hopefully that will lead to the identification of better treatment options for nonsmokers”

Determining risk factors that might place certain never-smokers at especially high risk for lung cancer is another focus of research The dream, experts said, is to somehow devise an accurate “panel” of biological and other factors that could serve as a basis in pinpointing at-risk individuals who may need closer monitoring

All of these research advances will depend on much better funding, however In the meantime, the stigma of smoking that overshadows never-smokers newly diagnosed with lung cancer continues

“We hear a lot from people that the first thing they are asked after diagnosis is, Did you smoke?” said Kawadler “Thats very tough”

Posted on November - 14 - 2011

FDA assigns new PDUFA date for Takeda’s investigational type 2 diabetes therapy, alogliptin

“Takeda is confident in alogliptin and alogliptin/pioglitazone as potential therapeutic options for the millions of patients living with type 2 diabetes,” said

Alogliptin is a highly potent and highly selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the U.S. for the treatment of type 2 diabetes as an adjunct to diet and exercise.

There is no change in Takeda’s fiscal 2011 financial outlook, which was announced on

Posted on November - 08 - 2011

Government allows infant-formula claims despite ‘no acceptable evidence’

 

OTTAWA — A major manufacturer of infant formula is being permitted to make health claims on product labels even though the federal government says there’s no “acceptable scientific evidence” to back them up, Postmedia News has learned.

Internal records from the Canadian Food Inspection Agency indicate it’s at an impasse with Health Canada when it comes to policing claims on two products marketed by Mead Johnson Nutrition, one of the largest makers of infant formula. And the issue may extend to other infant-formula makers as well.

Enfamil A+ has been on the market in Canada since 2002. En

Read more…